BDNF and cancer: The released proBDNF subsequently activates cellular myelocytomatosis oncogene (c-Myc)-regulated Egl-9 family hypoxia inducible factor 3 in neurons, enhancing cancer cell survival and resistance to therapy (Fig. 3b).